| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Carla Iarlori, Domenico Gambi, Francesco Gambi, Isabella Lucci, Claudio Feliciani, Mirella Salvatore, Marcella Real. Expression and production of two selected beta-chemokines in peripheral blood mononuclear cells from patients with Alzheimer's disease. Experimental gerontology. vol 40. issue 7. 2006-02-09. PMID:15935590. |
we sought to evaluate the role of these chemokines in alzheimer's disease (ad), and the effect of acetylcholinesterase inhibitor (achei) therapy on their release from peripheral blood mononuclear cells (pbmc). |
2006-02-09 |
2023-08-12 |
human |
| Tetsuya Shiraishi, Tatsuya Kikuchi, Kiyoshi Fukushi, Hitoshi Shinotoh, Shin-ichiro Nagatsuka, Noriko Tanaka, Tsuneyoshi Ota, Koichi Sato, Shigeki Hirano, Shuji Tanada, Masaomi Iyo, Toshiaki Iri. Estimation of plasma IC50 of donepezil hydrochloride for brain acetylcholinesterase inhibition in monkey using N-[11C]methylpiperidin-4-yl acetate ([11C]MP4A) and PET. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 30. issue 12. 2006-01-24. PMID:15920507. |
donepezil hydrochloride is a potent and selective inhibitor for brain acetylcholinesterase (ache) and is currently used worldwide for the treatment of alzheimer's disease. |
2006-01-24 |
2023-08-12 |
monkey |
| Esperanza Arias, Sonia Gallego-Sandín, Mercedes Villarroya, Antonio G García, Manuela G Lópe. Unequal neuroprotection afforded by the acetylcholinesterase inhibitors galantamine, donepezil, and rivastigmine in SH-SY5Y neuroblastoma cells: role of nicotinic receptors. The Journal of pharmacology and experimental therapeutics. vol 315. issue 3. 2006-01-23. PMID:16144975. |
donepezil, rivastigmine, and galantamine are three drugs with acetylcholinesterase (ache)-inhibiting activity that are currently being used to treat patients suffering from alzheimer's disease. |
2006-01-23 |
2023-08-12 |
human |
| Manami Kimura, Hiroko Komatsu, Hiroo Ogura, Kohei Sawad. Comparison of donepezil and memantine for protective effect against amyloid-beta(1-42) toxicity in rat septal neurons. Neuroscience letters. vol 391. issue 1-2. 2006-01-20. PMID:16154269. |
donepezil, a potent acetylcholinesterase (ache) inhibitor and memantine, an n-methyl-d-aspartate (nmda) receptor antagonist, have been used for the treatment of alzheimer's disease (ad), and both of them have been shown to have neuroprotective action against glutamate excitotoxicity. |
2006-01-20 |
2023-08-12 |
rat |
| Alexis Kays Leonard, Anthony P Sileno, Conor MacEvilly, Charles A Foerder, Steven C Quay, Henry R Costantin. Development of a novel high-concentration galantamine formulation suitable for intranasal delivery. Journal of pharmaceutical sciences. vol 94. issue 8. 2006-01-19. PMID:15986464. |
the goal of the current study was to develop an intranasal (in) formulation of the acetylcholinesterase inhibitor galantamine, an important therapeutic for treating alzheimer's disease. |
2006-01-19 |
2023-08-12 |
rat |
| Cássio M C Bottino, Isabel A M Carvalho, Ana Maria M A Alvarez, Renata Avila, Patrícia R Zukauskas, Sonia E Z Bustamante, Flávia C Andrade, Sérgio R Hototian, Fabiana Saffi, Candida H P Câmarg. Cognitive rehabilitation combined with drug treatment in Alzheimer's disease patients: a pilot study. Clinical rehabilitation. vol 19. issue 8. 2006-01-19. PMID:16323385. |
to study the efficacy of cognitive rehabilitation combined with acetylcholinesterase inhibitor (ache-i) treatment in patients with mild alzheimer's disease and their relatives. |
2006-01-19 |
2023-08-12 |
Not clear |
| Pilar Muñoz-Ruiz, Laura Rubio, Esther García-Palomero, Isabel Dorronsoro, María del Monte-Millán, Rita Valenzuela, Paola Usán, Celia de Austria, Manuela Bartolini, Vincenza Andrisano, Axel Bidon-Chanal, Modesto Orozco, F Javier Luque, Miguel Medina, Ana Martíne. Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer's disease. Journal of medicinal chemistry. vol 48. issue 23. 2006-01-17. PMID:16279781. |
design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for alzheimer's disease. |
2006-01-17 |
2023-08-12 |
Not clear |
| Nigel H Greig, Tadanobu Utsuki, Donald K Ingram, Yue Wang, Giancarlo Pepeu, Carla Scali, Qian-Sheng Yu, Jacek Mamczarz, Harold W Holloway, Tony Giordano, DeMao Chen, Katsutoshi Furukawa, Kumar Sambamurti, Arnold Brossi, Debomoy K Lahir. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent. Proceedings of the National Academy of Sciences of the United States of America. vol 102. issue 47. 2006-01-12. PMID:16275899. |
like acetylcholinesterase, butyrylcholinesterase (bche) inactivates the neurotransmitter acetylcholine (ach) and is hence a viable therapeutic target in alzheimer's disease, which is characterized by a cholinergic deficit. |
2006-01-12 |
2023-08-12 |
mouse |
| Bozena Bukowsk. [Acetylcholinesterase--apoptosis induction, role in neurological diseases and leukemia]. Postepy biochemii. vol 51. issue 2. 2005-12-20. PMID:16209353. |
it was found that a peptide derived from ache may induce neuronal death and acetylcholinesterase may induce neurological changes in the development of alzheimer's disease. |
2005-12-20 |
2023-08-12 |
Not clear |
| Bozena Bukowsk. [Acetylcholinesterase--apoptosis induction, role in neurological diseases and leukemia]. Postepy biochemii. vol 51. issue 2. 2005-12-20. PMID:16209353. |
the article is an attempt to explain the role of acetylcholinesterase in neuronal apoptosis, alzheimer's disease and myasthenia gravis as well as in leukemia. |
2005-12-20 |
2023-08-12 |
Not clear |
| Mariam F Eskander, Nicholas G Nagykery, Elaine Y Leung, Bahiyyih Khelghati, Changiz Geul. Rivastigmine is a potent inhibitor of acetyl- and butyrylcholinesterase in Alzheimer's plaques and tangles. Brain research. vol 1060. issue 1-2. 2005-12-20. PMID:16212945. |
acetylcholinesterase and butyrylcholinesterase activities emerge in association with plaques and tangles in alzheimer's disease. |
2005-12-20 |
2023-08-12 |
Not clear |
| John G Csernansky, Lei Wang, J Philip Miller, James E Galvin, John C Morri. Neuroanatomical predictors of response to donepezil therapy in patients with dementia. Archives of neurology. vol 62. issue 11. 2005-12-15. PMID:16286546. |
patients with dementia of the alzheimer type (dat) respond variably to treatment with acetylcholinesterase inhibitors. |
2005-12-15 |
2023-08-12 |
Not clear |
| Jan Mulder, Tibor Harkany, Katalin Czollner, Thomas I F H Cremers, Jan N Keijser, Csaba Nyakas, Paul G M Luite. Galantamine-induced behavioral recovery after sublethal excitotoxic lesions to the rat medial septum. Behavioural brain research. vol 163. issue 1. 2005-12-07. PMID:15951032. |
clinical trials show beneficial effects of acetylcholinesterase (ache) inhibitors, including galantamine, on cognitive functions in patients with mild to moderate alzheimer's disease. |
2005-12-07 |
2023-08-12 |
rat |
| Jacques Barik, Federico Dajas-Bailador, Susan Wonnacot. Cellular responses to nicotinic receptor activation are decreased after prolonged exposure to galantamine in human neuroblastoma cells. British journal of pharmacology. vol 145. issue 8. 2005-12-02. PMID:15937519. |
in this study, we have examined cellular responses of neuroblastoma sh-sy5y cells after chronic treatment with galantamine, a drug used to treat alzheimer's disease that has a dual mechanism of action: inhibition of acetylcholinesterase and allosteric potentiation of nicotinic acetylcholine receptors (nachr). |
2005-12-02 |
2023-08-12 |
human |
| Alina Borkowska, Marzena Ziolkowska-Kochan, Janusz K Rybakowsk. One-year treatment of Alzheimer's disease with acetylcholinesterase inhibitors: improvement on ADAS-cog and TMT A, no change or worsening on other tests. Human psychopharmacology. vol 20. issue 6. 2005-12-02. PMID:15991260. |
one-year treatment of alzheimer's disease with acetylcholinesterase inhibitors: improvement on adas-cog and tmt a, no change or worsening on other tests. |
2005-12-02 |
2023-08-12 |
Not clear |
| Alina Borkowska, Marzena Ziolkowska-Kochan, Janusz K Rybakowsk. One-year treatment of Alzheimer's disease with acetylcholinesterase inhibitors: improvement on ADAS-cog and TMT A, no change or worsening on other tests. Human psychopharmacology. vol 20. issue 6. 2005-12-02. PMID:15991260. |
the aim of this study was to assess cognitive functioning measured by selected psychometric and neuropsychological tools in patients with alzheimer's disease (ad) after 1-year treatment with acetylcholinesterase inhibitors. |
2005-12-02 |
2023-08-12 |
Not clear |
| Hong Nga Nguyen, Dae Youn Hwang, Young Kyu Kim, Do Young Yoon, Jae Hwa Kim, Moon Soon Lee, Myung Koo Lee, Yeo Pyo Yun, Ki Wan Oh, Jin Tae Hon. Mutant presenilin 2 increases acetylcholinesterase activity in neuronal cells. Archives of pharmacal research. vol 28. issue 9. 2005-11-28. PMID:16212240. |
these results suggest that a mutant presenilin 2-induced neurodegeneration in alzheimer's disease might be involved in the increase in acetylcholinesterase activity. |
2005-11-28 |
2023-08-12 |
mouse |
| Huai Yong Chen. Evidence of acetylcholinesterase inhibitors in treating Alzheimer's disease in very old patients is uncertain. Journal of the American Geriatrics Society. vol 53. issue 9. 2005-11-07. PMID:16137311. |
evidence of acetylcholinesterase inhibitors in treating alzheimer's disease in very old patients is uncertain. |
2005-11-07 |
2023-08-12 |
Not clear |
| Giacoma C Sorrentino, Bruno Caffari, Nicola Vanacore, Marina Maggini, Roberto Raschett. [The characteristics of Alzheimer's Disease Units in relation to neuropsychological tests]. Annali dell'Istituto superiore di sanita. vol 41. issue 1. 2005-10-28. PMID:16037652. |
the cronos project is a post-marketing surveillance study implemented by the italian ministry of health and the national institute of health whose main objectives are to characterise the population of alzheimer's disease patients treated with acetylcholinesterase inhibitors and monitor effectiveness and drug safety in the field practice. |
2005-10-28 |
2023-08-12 |
Not clear |
| Donna M Byers, Louis N Irwin, Donald E Moss, Isabel C Sumaya, Christine F Hohman. Prenatal exposure to the acetylcholinesterase inhibitor methanesulfonyl fluoride alters forebrain morphology and gene expression. Brain research. Developmental brain research. vol 158. issue 1-2. 2005-10-27. PMID:15964079. |
methanesulfonyl fluoride (msf) is a cns-selective acetylcholinesterase (ache) inhibitor, currently being developed and tested for the treatment of symptoms of alzheimer's disease. |
2005-10-27 |
2023-08-12 |
rat |